Current Trials

Here are our trials as of February 25, 2015:

  • Bladder Cancer

    • No trials available at this time
  • Brain Cancer

    • No trials available at this time
  • Breast Cancer

    • A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Verses the Addition of Carbopatin to Standard Neoadjuvant Chemotherapy Verses Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)  (AbbVie M14-011)
    • A Phase I dose escalation study of LEE011 in combination with buparlisib and letrozole for the treatment of HR+, HER2-negative post-menopausal women with locally advanced or metastatic breast cancer (Novartis CLEE011A2112C)
    • A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with FGF aberrant metastatic breast cancer (Clovis CO-3810-025)
    • A Phase 2, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients with Recurrent Brain Metastases (Angiochem ANG1005-CLN-04)
  • Colorectal Cancer

    • A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination with Regorafenib in Subjects with Relapsed or Refractory Metastatic Colorectal Cancer (Incyte INCB 18424-267)
    • A Data Collection study for Patients with Metastatic Castration Resistant Prostate Cancer for which they received at least one Provenge infusion within the past 3 months (MedTrend)
    • Prospective International Observational Study Describing the Safety and Effectiveness of ZALTRAP Administered in Combination with FOLFIRI for the Treatment of Patients with Metastatic Colorectal Cancer in Clinical Practice (Sanofi OBS13597)
    • A Phase 4 Open-Label Trial with Regorafenib in Metastatic Colorectal Cancer (Bayer BAY73-4506)
  • Esophageal Cancer

    • No trials available at this time
  • Gastric Cancer

    • No trials available at this time
  • Genitourinary Cancer

    • No trials available at this time
  • Head and Neck Cancer

    • No trials available at this time
  • Leukemia

    • A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins in Patients with Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms (Constellation Pharmaceuticals 0610-02)
    • Prospective, Non-interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera (Incyte INCV-MAPV-401)
  • Lung Cancer

    • A Phase Ib/II, Multicenter, Open-Label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-Stage Small Cell Lung Cancer (Onyx CFZ004)
    • A Randomized, Double-blind Phase 2 Study of Ruxolitinib or Placebo in Combination with Premetrexed/ Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects with Nonsquamous Non-Small Cell Lung Cancer that is Stage IIIb with Pleural/ Pericardial Effusion, Stage IV, or Recurrent  (Incyte INCB 18424-266)
    • Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (AbbVie MM11-089)
    • Open-label, Multicenter Phase 1 Study of Mogamulizumab in Combination with Docetaxel as Second-Line Treatment in Submects with Non-Small Cell Lung Cancer (Kyowa 0761-011)
  • Lymphoma

    • Phase 1/2 Open-Label, Multi-dose, Dose Escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia (Idera 8400-401)
    • A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ProNAi PNT2258-02)
    • Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Toelrability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and MyD88 L265P Mutation (Idera 8400-402)
    • An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia who Completed Study 8400-401 (Idera 8400-404)
    • A Phase 1 Dose Escalation Study of ARW092 in Adult Subjects with Advanced Solid Tumors and Recurrent Malignant Lymphoma (ArQule ARQ092-101)
    • A Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (ProNAi PNT2258-03)
    • A Phase1b/2 Study Evaluating the Safety, Tolerability and Anti-tumor Activity of Polatuzumab Vedotin in Combination with Rituximab or Obinutuzumab Plus Bendamustine in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (Genentech GO29365)
    • A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas (Constellation 1205-01)
  • Myelodysplastic Syndrome

    • A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins in Patients with Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms (Constellation Pharmaceuticals 0610-02)
  • Multiple Myeloma

    • A Phase I/II Study of Weekly Carfilzomib in Combination with Dexamethasone for Progressive Multiple Myeloma (Onyx 2012-002)
    • A Multicenter, Open-label, Phase Ib Study of Carfilzomib, Cyclophosphamide and Dexamethason in Newly Diagnosed Multiple Myeloma Subjects (Onyx 2012-003)
    • A Phase 1b/2 Multicenter, Open-labe, Dose-escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (Acetylon ACE-MM-102)
    • A Phase 2 Single Arm Study of Safety of Elotuzumab Administered over Approximately 60 minutes in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients (Bristol Myers Squibb CA204112)
  • Ovarian Cancer

    • A Phase Ib Dose Escalation Study of MEL162 in Combination with Weekly Paclitaxel in Patients with Platinum Resistant Ovarian , Fallopian Tube or Primary Peritoneal Cancer (Array 162-112)
    • A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Clovis CO-338-017)
  • Pancreatic Cancer

    • No trials available at this time
  • Prostate Cancer

    • No trials available at this time
  • Rectal Cancer

    • A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination with Regorafenib in Subjects with Relapsed or Refractory Metastatic Colorectal Cancer (Incyte INCB 18424-267)
  • Solid Tumors

    • A Phase I/Ib, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617, A Human Monoclonal Antibody Directed Against ANG2, as a Single-Agent or in Combination Therapy in Adult Subjects with Advanced Solid Tumors (MedImmune CD-ON-MEDI3617-1043)
    • A Phase I and Pharmacologic Study of MM-151 in Patients with Refractory Advanced Solid Tumors (Merrimack MM-151-01-01-01)
    • A Phase I Study of Folic Acid-Tubulysis Conjugate EC1456 in Patients with Advanced Solid Tumors (Endocyte EC1456-01)
    • A Phase Ib, open label, dose finding study of BYL719 in combination with paclitaxel in advanced solid tumors followed by two expansion phases in locally advanced/ metastatic chemotherapy naive HER2-breast cancer patients and recurrent or metastatic head-and-neck squamous cell carcinoma patients pre-treated with platinum based therapy (Novartis CBYL719Z2101)
  • Miscellaneous

    • A Registry of Caris Target Now Test Results and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and Other Patients (Caris Registry TCREG-001-00-V201209)
    • A Registry of Hematopoietic Diseases for Evaluation of Correlation with Clinical Outcomes (Miraca Life Sciences MRIREG-0001-03/12)